| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8790042 | Urologic Oncology: Seminars and Original Investigations | 2018 | 9 Pages |
Abstract
Based on these data, we suggest that DNA damage levels measured in PBMCs of patients with BC may potentially represent a prognostic marker associated with poor survival; further validation is needed to better stratify patients with BC for clinical trials.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Alessandra Ph.D., Barbara Ph.D., Clara Ph.D., Marco M.D., Marco M.D., Paolo M.D., Paolo M.D., Carlotta M.D., Ph.D., Giuseppe Ph.D.,